Moderna Inc (MRNA)
Return on equity (ROE)
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net income (ttm) | US$ in thousands | -4,714,000 | -3,466,000 | 1,207,000 | 4,784,000 | 8,362,000 | 11,765,000 | 14,055,000 | 14,638,000 | 12,202,000 | 7,061,000 | 3,495,000 | 598,000 | -747,000 | -597,269 | -487,484 | -505,424 | -514,000 | -532,123 |
| Total stockholders’ equity | US$ in thousands | 13,854,000 | 13,455,000 | 16,949,000 | 18,863,000 | 19,123,000 | 17,992,000 | 17,985,000 | 17,075,000 | 14,145,000 | 10,124,000 | 6,704,000 | 3,838,000 | 2,561,000 | 2,760,000 | 2,947,000 | 1,641,000 | 1,175,000 | 1,248,190 |
| ROE | -34.03% | -25.76% | 7.12% | 25.36% | 43.73% | 65.39% | 78.15% | 85.73% | 86.26% | 69.75% | 52.13% | 15.58% | -29.17% | -21.64% | -16.54% | -30.80% | -43.74% | -42.63% |
December 31, 2023 calculation
ROE = Net income (ttm) ÷ Total stockholders’ equity
= $-4,714,000K ÷ $13,854,000K
= -34.03%
Moderna Inc's return on equity (ROE) has displayed significant fluctuations over the past eight quarters. In Q1 2022, the company reported a robust ROE of 85.73%, indicating efficient utilization of shareholder equity to generate profits. This was followed by a consistent decline in ROE in subsequent quarters, dropping to 78.15% in Q2 2022 and further to 65.39% in Q3 2022.
However, a notable turnaround was observed in Q4 2022, as Moderna Inc's ROE surged to 43.73%, showcasing an improvement in profitability and efficiency. This positive momentum was short-lived, with a sharp decline in ROE to 25.36% in Q1 2023.
The trend reversed drastically in the most recent quarters, with Moderna Inc reporting negative ROE figures. In Q2 2023, the company achieved an ROE of 7.12%, only to witness a significant decline to -25.76% in Q3 2023 and a further decrease to -34.03% in Q4 2023.
Overall, Moderna Inc's ROE trend reflects a volatile performance in terms of generating profits from shareholder equity. The company experienced periods of strong profitability followed by declines and negative returns, indicating fluctuations in operational efficiency and profitability levels. Further analysis and monitoring of the factors impacting ROE will be crucial for investors and stakeholders to assess Moderna Inc's financial health and performance in the future.
Peer comparison
Dec 31, 2023